BWV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 Dec 2023 @ 15:59):

Stats
Today's Volume	520 290
Average Volume	435 531
Market Cap	3.41M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.167
ATR14	$0.0440 (25.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-15	Schiess Ralph	Sell	0	Common Stock
2023-12-15	Bruhlmann Christian	Sell	0	Common Stock
2023-10-04	Campbell Neil J	Sell	532 326	Stock Option
2023-10-04	Harmon Bruce	Sell	177 442	Stock Option
2023-05-31	Jeremic Vuk	Buy	6 360	Common Stock

INSIDER POWER
-70.74
Last 40 transactions
Buy: 4 886 577 \| Sell: 8 258 116

Volume Correlation

Long: -0.25 (neutral)

Short: -0.68 (moderate negative)

Signal:(32.398) Neutral

iPath Goldman Sachs Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

iPath Goldman Sachs Correlation - Currency/Commodity

-0.78
( moderate negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

-0.19
( neutral )

0.34
( neutral )

iPath Goldman Sachs Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.080

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.080

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.309

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.195

Financial Reports:

No articles found.

iPath Goldman Sachs

Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.